The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.

Chronic obstructive pulmonary disease (COPD) burden remains high in underdeveloped regions of China despite a decline in ...

Global medical companies are launching hundreds of state-of-the-art technologies in the medical product pavilion of the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. "Regeneron had a strong third quarter marked by 11% ...

Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for certain inflammatory conditions. Dupixent has interactions with some other drugs. Examples include certain ...

Regeneron recently secured approval for Dupixent in treating Chronic Obstructive Pulmonary Disease (COPD) in the European Union, with a pending approval decision in the United States expected in the ...

Profits at China’s industrial firms in September declined at a faster pace than a month earlier, as deflationary pressures sap the strength of corporate finances. Last month’s industrial ...

Dupixent is now approved for COPD in more than 30 countries, including the US and China, where COPD is a huge unmet medical ...

Twin sisters in China were reunited after 30 years, only to become estranged following unsuccessful business ventures, with one sister disappearing with the start-up funds. The twins, originally ...